Bavarian Nordic (OTCMKTS:BVNRY) versus Milestone Pharmaceuticals (NASDAQ:MIST) Head to Head Comparison

Milestone Pharmaceuticals (NASDAQ:MIST) and Bavarian Nordic (OTCMKTS:BVNRY) are both medical companies, but which is the better business? We will compare the two companies based on the strength of their valuation, dividends, profitability, institutional ownership, risk, analyst recommendations and earnings.

Profitability

This table compares Milestone Pharmaceuticals and Bavarian Nordic’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Milestone Pharmaceuticals	N/A	-339.33%	-61.79%
Bavarian Nordic	19.74%	9.32%	8.14%

Earnings & Valuation

This table compares Milestone Pharmaceuticals and Bavarian Nordic”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Milestone Pharmaceuticals	$1.55 million	99.60	-$63.06 million	($0.68)	-1.82
Bavarian Nordic	$945.43 million	2.28	$208.23 million	$0.76	11.91

Bavarian Nordic has higher revenue and earnings than Milestone Pharmaceuticals. Milestone Pharmaceuticals is trading at a lower price-to-earnings ratio than Bavarian Nordic, indicating that it is currently the more affordable of the two stocks.

Volatility and Risk

Milestone Pharmaceuticals has a beta of 0.95, meaning that its share price is 5% less volatile than the S&P 500. Comparatively, Bavarian Nordic has a beta of 1.19, meaning that its share price is 19% more volatile than the S&P 500.

Insider & Institutional Ownership

86.2% of Milestone Pharmaceuticals shares are owned by institutional investors. 5.0% of Milestone Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a summary of recent ratings for Milestone Pharmaceuticals and Bavarian Nordic, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Milestone Pharmaceuticals	2	0	3	1	2.50
Bavarian Nordic	0	0	0	0	0.00

Milestone Pharmaceuticals presently has a consensus target price of $7.25, suggesting a potential upside of 484.68%. Given Milestone Pharmaceuticals’ stronger consensus rating and higher probable upside, equities analysts clearly believe Milestone Pharmaceuticals is more favorable than Bavarian Nordic.

Summary

Bavarian Nordic beats Milestone Pharmaceuticals on 8 of the 15 factors compared between the two stocks.

About Milestone Pharmaceuticals

Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines. The company's lead product candidate is etripamil, a novel and potent calcium channel blocker, which is in Phase III clinical trial for the treatment of paroxysmal supraventricular tachycardia in the United States and Canada; and Phase II clinical trial for the treatment of atrial fibrillation and rapid ventricular rate. It has a license and collaboration agreement with Ji Xing Pharmaceuticals to develop and commercialize etripamil prophylactic and therapeutic uses in humans, as well as with the Montreal Heart Institute, the WCN network, and other research centers. The company was incorporated in 2003 and is headquartered in Montréal, Canada.

About Bavarian Nordic

Bavarian Nordic A/S develops, manufactures, and commercializes life-saving vaccines. The company offers non-replicating smallpox and monkeypox vaccines under the IMVAMUNE, IMVANEX, and JYNNEOS names; rabies vaccine for human use under the Rabipur/RabAvert name; tick-borne encephalitis vaccine under the Encepur name; and Ebola vaccine under the MVABEA name. It is also developing MVA-BN for the treatment of smallpox; MVA-BN RSV, which is in Phase III clinical trials for the treatment of respiratory syncytial virus; ABNCoV2 that has completed Phase III clinical trial for the treatment of SARS-CoV-2. The company has license and collaboration agreement with AdaptVac; and license agreements with National Cancer Institute and Public Health Service. It operates in the United States, Canada, France, Germany, Spain, Australia, Switzerland, Sweden, Chile, Taiwan, the United Kingdom, Hong Kong, Saudi Arabia, Belgium, and internationally. Bavarian Nordic A/S was incorporated in 1992 and is headquartered in Hellerup, Denmark.